News
ONC
417.33
+2.55%
10.37
BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus
Simply Wall St · 8h ago
Weekly Report: what happened at ONC last week (1102-1106)?
Weekly Report · 12h ago
Is BeOne Medicines (ONC) Fully Priced After Its 104% Run?
Simply Wall St · 1d ago
Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance
Simply Wall St · 2d ago
BeOne Medicines Ltd (6160) Gets a Buy from CICC
TipRanks · 2d ago
UBS Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
TipRanks · 2d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
BeOne Medicines Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
BeOne Medicines Price Target Raised to $465.00/Share From $459.00 by RBC Capital
Dow Jones · 3d ago
BeOne Medicines Price Target Raised to $448.00/Share From $420.00 by Truist Securities
Dow Jones · 3d ago
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465
Benzinga · 3d ago
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448
Benzinga · 3d ago
BeOne Medicines Price Target Raised to $446.00/Share From $415.00 by Barclays
Dow Jones · 3d ago
BeOne Medicines Is Maintained at Overweight by Barclays
Dow Jones · 3d ago
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446
Benzinga · 3d ago
BeOne Medicines Is Maintained at Market Outperform by Citizens
Dow Jones · 3d ago
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463
Benzinga · 3d ago
BeOne Medicines Price Target Raised to $435.00/Share From $400.00 by Wells Fargo
Dow Jones · 3d ago
BeOne Medicines Is Maintained at Overweight by Wells Fargo
Dow Jones · 3d ago
CMB International Securities Keeps Their Buy Rating on BeOne Medicines (ONC)
TipRanks · 3d ago
More
Webull provides a variety of real-time ONC stock news. You can receive the latest news about BeOne Medicines Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.